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Tuberculosis (TB) remains a major global health problem; 10 million new cases were reported 
in 2018 (1). In Sudan, the estimated national TB in-
cidence in 2018 was 71/100,000 persons; a total of 
20,638 cases were reported (1). However, the TB bur-
den is by no means homogeneous across the coun-
try. For instance, in eastern Sudan, TB notifications 
reached 275/100,000 persons in 2012 (2,3). Prevalence 
of multidrug-resistant TB (MDR TB) (i.e., resistant to 
isoniazid and rifampin) was estimated at 2.9% in new 
and 13% in retreatment cases; however, studies have 
reported MDR TB rates of 6%–22% (1,4–10).
Ongoing transmission is one of the key challenges 
for TB control programs, especially in countries with 
a high TB burden (1,11). In recent years, molecular 
techniques have been increasingly used to clarify and 
trace transmission of Mycobacterium tuberculosis com-
plex (MTBC) strains and to direct and guide targeted 
TB control actions (12,13). However, availability of 
molecular techniques is limited in many countries in 
Africa with a high TB burden (11).
In Sudan, drug-resistant TB often goes undetect-
ed, resulting in inadequate treatment, illness, death, 
and ongoing transmission (1,14). Local laboratories 
have limited access to mycobacterial culture and drug 
susceptibility testing (DST) or DNA-based techniques 
(14). Therefore, MDR TB rates might be underesti-
mated in eastern Sudan. In addition, mutations that 
mediate drug resistance have not been investigated.
Taken together, these factors indicate that, al-
though TB is a huge health problem in eastern Su-
dan, precise data on the phylogeny and transmission 
dynamics of MTBC strains, as well as on resistance 
patterns, is sparsely available (2,3,7,8,15). Studies 
using molecular epidemiologic tools are rare and 
have used classical genotyping techniques, such as 
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Pathogen-based factors associated with tuberculosis 
(TB) in eastern Sudan are not well defined. We inves-
tigated genetic diversity, drug resistance, and possible 
transmission clusters of Mycobacterium tuberculosis 
complex (MTBC) strains by using a genomic epidemiol-
ogy approach. We collected 383 sputum specimens at 3 
hospitals in 2014 and 2016 from patients with symptoms 
suggestive of TB; of these, 171 grew MTBC strains. 
Whole-genome sequencing could be performed on 
166 MTBC strains; phylogenetic classification revealed 
that most (73.4%; n = 122) belonged to lineage 3 (L3). 
Genome-based cluster analysis showed that 76 strains 
(45.9%) were grouped into 29 molecular clusters, com-
prising 2–8 strains/patients. Of the strains investigated, 
9.0% (15/166) were multidrug resistant (MDR); 10 MDR 
MTBC strains were linked to 1 large MDR transmission 
network. Our findings indicate that L3 strains are the 
main causative agent of TB in eastern Sudan; MDR TB 
is caused mainly by transmission of MDR L3 strains.
SYNOPSIS
spoligotyping, which cannot deduce direct transmis-
sion events (5,15). New techniques, such as whole-
genome sequencing (WGS), offer the highest reso-
lution for MTBC genotyping and provide precise 
information on resistance mutations (16,17). We ap-
plied state-of-the-art phenotypic and molecular as-
says to investigate specimens collected from patients 
with symptoms suggestive of pulmonary TB, includ-
ing new and retreatment cases, to analyze the MTBC 
population structure, putative transmission events, 
and DST profiles in eastern Sudan.
Methods
Study Design and Setting
We recruited patients with symptoms suggestive of 
pulmonary TB who had positive sputum smears and 
agreed to participate in this cross-sectional study. 
Patients had been treated in the outpatient depart-
ments at public hospitals in Kassala, Port Sudan, and 
El-Gadarif in eastern Sudan over 2 recruitment peri-
ods, June–October 2014 and January–July 2016. We 
collected spot and early morning sputum samples. 
If 1 sample was smear positive, the 2 samples were 
pooled and stored for <6 months at –20°C. Shortly 
before we shipped each sample to the National Ref-
erence Center (NRC) for Mycobacteria, Borstel, Ger-
many, we transferred a volume of <2 mL to a screw-
capped Eppendorf tube; the samples were shipped in 
2 separate batches.
Mycobacterial Culture and Identification
Sample decontamination, smear microscopy, and 
mycobacterial culture were performed at the NRC 
(18,19). We extracted DNA using a QIAamp DNA 
Mini Kit 250 (QIAGEN, https://www.qiagen.com) 
according to the instructions of the manufacturer for 
quantitative PCR (qPCR). We extracted DNA by the 
boiling/sonication method for conducting line probe 
assays (LPAs) such as GenoType Mycobacterium CM 
and GenoType Mycobacterium MTBC (Hain Life-
science, https://www.hain-lifescience.de) (19). We 
used cetyl trimethylammonium bromide for DNA 
extraction for WGS (20). We transferred the extracted 
DNA to new Eppendorf tubes and stored it at –20°C 
until used.
We used an in-house qPCR detecting MTBC and 
nontuberculous mycobacteria (NTM) DNA to test 
available culture-negative/contaminated samples 
(21). We ran the qPCR experiments using the Rotor-
Gene 2000 (Corbett Research Pty Ltd, http://www.
australianexporters.net). We used LPAs (Hain Life-
science, https://www.hain-lifescience.de) according 
to the manufacturer’s instructions to classify isolated 
mycobacteria into MTBC or NTM and to differentiate 
the MTBC species. 
We identified NTM species using 16S rRNA, 
internal transcribed spacer (ITS) DNA fragment se-
quencing, or both (22). We sequenced the complete 
PCR products on an automated DNA sequencer (ABI 
377; Applied Biosystems, https://www.thermofish-
er.com) by cycle sequencing using the Big Dye RR 
Terminator Cycle Sequencing Kit (Applied Biosys-
tems). We aligned the resulting sequences and com-
pared them with the sequences of the International 
Nucleotide Sequence Database Collaboration.
Drug Susceptibility Testing
We performed phenotypic DST (pDST) for resis-
tance to streptomycin 1 µg/mL, isoniazid 0.1 µg/
mL, rifampin 1 µg/mL, ethambutol 5 µg/mL, and 
pyrazinamide 100 µg/mL for all MTBC isolates (18). 
We further investigated isolates with resistance to >1 
first-line drug for resistance to ofloxacin 2 µg/mL, 
amikacin 1 µg/mL, and capreomycin 2.5 µg/mL (23).
We further evaluated strains that had a mu-
tation in the embB codons 306, 406, or 497 (as de-
tected by WGS) but tested phenotypically suscep-
tible to ethambutol at the critical concentration 
by determining ethambutol MICs. We assessed 
concentrations of 1.25, 2.5, 3.75, and 5.0 µg/mL in 
the BACTEC MGIT 960 system (Becton Dickinson, 
https://www.bd.com) (24,25).
WGS
We performed WGS using the Illumina Nextera (XT) 
kit (https://www.illumina.com) (26). We sequenced 
isolates with a minimum average genome coverage 
of 50×. We used single-nucleotide polymorphisms 
(SNPs) occurring in >4 forward and >4 reverse reads, 
4 reads calling the allele with a Phred score >20, and 
a minimum variant frequency of 75% for a concat-
enated sequence alignment (27). In the comparative 
genomic analysis, we allowed 5% of all samples to 
miss these coverage and frequency thresholds at indi-
vidual positions and called the majority allele (>50% 
variant frequency) to not lose sequence information 
in genome regions with lower average coverage. We 
excluded repetitive region and drug resistance associ-
ated genes for phylogenetic reconstruction.
Phylogenetic Inference
We calculated a maximum-likelihood tree with Fast-
Tree using the concatenated sequence alignment 
and a general time-reversible substitution model 
(28). We conducted inspection and rooting of the 
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maximum likelihood tree using FigTree software 
and performed the graphical presentation using 
the online tool EvolView (29). We calculated maxi-
mum parsimony trees with BioNumerics version 7.6 
(Applied Maths, https://www.applied-maths.com) 
using the concatenated sequence alignment (30).
Molecular Drug Resistance Prediction
We screened the rpsL, rrs, and gidB genes for mutations 
that confer resistance to streptomycin and the katG and 
inhA genes and the fabG1-inhA promoter for resistance 
to isoniazid (31). We inferred rifampin resistance by 
mutations in the rpoB gene. Moreover, we also noted 
putative compensatory mutations in the rpoA and rpoC 
genes (for rifampin resistance) and the ahpC gene (for 
isoniazid resistance). We investigated the embA, embB, 
and embC genes for resistance conferring mutations to 
ethambutol and screened the pncA gene for mutations 
associated with resistance to pyrazinamide (31). We 
investigated the gyrA and gyrB genes for resistance to 
fluoroquinolones and investigated the rrs gene for re-
sistances against kanamycin, amikacin, and capreomy-
cin. In addition, we screened the eis promoter region 
for resistance against KAN and the tlyA for resistance 
against capreomycin. For ethionamide, we investigat-
ed the ethA and inhA genes and the fabG1-inhA promot-
er and for para-aminosalicylic acid, we investigated 
the ribD, thyA, thyX, and folC genes (31).
Statistics
We used SPSS version 20.0 (https://www.ibm.com) 
for all appropriate statistical analyses. We obtained 
descriptive statistics of the variables, including fre-
quencies and proportions. We analyzed differences 
between groups by using the χ2 or Fisher exact test; 
p<0.05 denoted statistical significance (32).
Ethics Considerations
Scientific and ethics approval for the study was pro-
vided by the National Research Ethics Committee, 
Federal Ministry of Health, Khartoum, Sudan, and 
by the Institutional Review Board of the Institute of 
Endemic Diseases, University of Khartoum, Khar-
toum, Sudan (no. 85–03–09). We obtained written 
informed consent for participation in the study from 
participants or, in case of children or illiterate pa-
tients, their guardians.
Results
Study Population
Sputum samples were provided by smear-positive 
patients with TB from 3 areas in eastern Sudan in 
2014 (n = 101) and 2016 (n = 282) (Figure 1). Based on 
hospital records, we included 10%–20% of all patients 
who received diagnoses of TB during the study pe-
riod. We collected patient-derived samples from 161 
patients (42%) in El-Gadarif, 133 patients (34.7%) in 
Kassala, and 89 patients (23.3%) in Port Sudan hos-
pitals. Patients who provided samples had a medi-
an age of 35 years (interquartile range 25–45 years); 
most (245/383; 66%) were male. In addition, 81.5% 
(312/383) were new and 5.5% (21/383) were retreat-
ment TB cases; data on TB treatment history were 
unavailable for 13.0% (50/383) (Table 1). Comparison 
of the 2 patient cohorts revealed no significant differ-
ence between the proportions of L3 strains (p = 0.068 
by Fisher exact test) but the 2014 cohort contained 
more drug-resistant (p = 0.019 by Fisher exact test) 
and clustered (p = 0.016 by Fisher exact test) strains 
(Table 2).
Mycobacterium Isolation and Species Identification
Of all collected specimens, 51.2% (196/383) were 
culture positive for mycobacteria; LPAs identified 
most (n = 171, 87.2%) as MTBC (Figure 1). The rest 
of the specimens were either culture negative or con-
taminated; we tested them with qPCR and Sanger se-
quencing for mycobacterial DNA detection and spe-
cies identification (Figure 1) (14).
MTBC Population Structure and Genome-Based Clusters
We performed WGS successfully on 166 MTBC 
strains. We built a maximum-likelihood phylogeny 
upon a concatenated sequence alignment compris-
ing 11,932 SNPs to investigate the MTBC population 
structure (Figure 2). We performed MTBC (sub)lin-
eage (L) classification with an SNP bar code nomen-
clature that was recently introduced (33). Strains of 
L3 (Delhi/CAS) were predominant (73.5%, 122/166), 
followed by L4 (Euro-American) strains (23.5%, 
39/166). We further classified L4 strains into several 
sublineages (Appendix 1 Figure 1, https://wwwnc.
cdc.gov/EID/article/26/3/19-1145-App1.pdf). The 
remaining isolates belonged to L1 (2.4%, 4/166) and 
L2 (0.6%, 1/166). 
To obtain an indication about putative recent 
transmission events, we conducted a cluster analysis 
based on a pairwise SNP distance of <12 SNPs be-
tween any 2 strains (12,34). Overall, 45.9% (76/166) 
of the strains were grouped in 29 clusters compris-
ing 2–8 isolates/patients (Appendix 1 Figure 2). L3 
strains were observed with a higher clustering rate 
(52.5%, 64/122) than L4 isolates (28.2%, 11/39) (p = 
0.016 by Fisher exact test). Two of the 4 L1 strains 
were clustered; no L2 strains were assigned to a WGS 
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cluster. Moreover, considering a stricter threshold (<5 
SNPs), 36.7% (61/166) isolates were still connected in 
24 clusters comprising 2–8 isolates/patients (Appen-
dix 1 Figure 3).
pDST and Genotypic DST
To determine resistance levels and related genomic 
variants, we performed pDST and genomic resistance 
predictions or genotypic DST (gDST) and compiled 
detailed data on resistances and resistance confer-
ring mutations (Tables 3, 4; Appendix 1 Table). Over-
all, 21.7% (36/166) of the strains showed resistance 
to >1 of the tested first-line antimicrobial drugs by 
pDST, including 15 (9.0%) MDR and 21 (12.7%) non-
MDR strains (Appendix 2,  https://wwwnc.cdc.gov/
EID/article/26/3/19-1145-App2.xlsx). Strikingly, all 
MDR and 76.1% of non-MDR strains belonged to L3. 
Furthermore, beyond the MDR classification, we 
found that L3 strains in eastern Sudan were more of-
ten found with drug resistances as compared with L4 
strains (L3, 31/122, 25.4%; L4, 4/39, 10.3%; p = 0.048 
by  Fisher exact test). 
We detected resistance to streptomycin in 19.9% 
(33/166) of the strains, mediated by mutations in 
rspL (Lys43Arg, Lys88Arg, and Lys88Met), gidB (e.g., 
Ala138Val), and rrs (514, a/c) genes. We observed 
all isoniazid-resistant strains (10.2%, 17/166) either 
with a mutation in katG (Ser315Thr and Ser315Asn) 
that changes catalase–peroxidase activities or in the 
promoter region of the drug target InhA, fabG1-inhA 
(–15 c/t), which also confers resistance to the second-
line drug ETH. Resistance to rifampin was found in 
10.2% (17/166) of the strains and was mediated by 
mutations in the rpoB gene (Ser450Leu, His445Tyr, 
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Figure 1. Work flow for study 
of Mycobacterium tuberculosis 
complex lineage 3 as causative 
agent of pulmonary tuberculosis, 
eastern Sudan. LPAs, HAIN line 
probe assay for GenoType CM 
and GenoType MTBC; MGIT, 
mycobacteria growth indicator 
tube; MTBC, Mycobacterium 
tuberculosis complex; mix, 2 
different bacteria grew on the 
same culture; NALC-NaOH, 
sodium hydroxide/N-acetyl-
cysteine; NTM, nontuberculous 
mycobacteria; pDST, phenotypic 
drug susceptibility testing; WGS, 
whole genome sequencing. 
Adopted from Shuaib et al. (14).
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His445Asn, and His445Asp). We found 1 ethambu-
tol-resistant strain (0.6%) with the mutation embB 
Gln497Arg. However, we also detected 11 additional 
mutations associated with ethambutol resistance in 
the embB gene (10 Met306Ile and 1 Met306Val) but 
with MICs ranging from 1.25 to 5 µg/mL, classifying 
these strains as phenotypically susceptible based on 
the recommended critical concentration for etham-
butol. With regard to pyrazinamide, we identified 1 
strain (0.6%) with the mutation pncA Gln10Arg, coin-
ciding with phenotypic pyrazinamide resistance.
A detailed comparison of the pDST and gDST 
results revealed a high sensitivity and specificity for 
isoniazid, rifampin, and pyrazinamide resistance pre-
diction by WGS (Table 4). For ethambutol, we deter-
mined high-confidence resistance SNPs at codon 306, 
406, or 497; however, varying levels of ethambutol 
MICs in the strains with mutations resulted in a very 
low positive predictive value. For streptomycin, we 
considered the gidB mutations (Phe12Ser, Arg39Pro, 
Trp45STP, Ser136STP, Iso114Ser, and deletions at 
positions 4408101, 4408017, and 4408116) to be muta-
tions with an unclear effect. However, these strains 
eventually tested phenotypically resistant to strepto-
mycin, leading to a reduced sensitivity.
All strains with resistances to >1 first-line antimi-
crobial drug were phenotypically and genotypically 
susceptible to ofloxacin, capreomycin, and amikacin. 
We identified no genotypic resistance marker mediat-
ing para-aminosalicylic acid resistance.
Based on a 12-bp SNP threshold between any 2 
strains, 80.0% (12/15) of the MDR strains were clus-
tered or connected (i.e., associated with recent trans-
mission); based on <5 SNPs distance, 60% (9/15) of 
the MDR strains were clustered (Appendix 1 Figure 
4, panel A). Most of the clustered strains at <12 SNPs 
were isolated from patients in Kassala and grouped 
in clusters 4 and 29. These strains also shared the 
same rpsL (Lys43Arg) and the katG (Ser315Thr) mu-
tations but harbored different mutations in the rpoB 
gene; strains of cluster 4 had the Ser450Leu mutation, 
whereas strains of cluster 29 exhibited a His445Tyr 
mutation. This finding points toward a close relation-
ship between the strains of both clusters that likely 
emerged from a common recent ancestor already be-
ing polyresistant to streptomycin and isoniazid (Ap-
pendix 1 Figure 4, panel B). Furthermore, all 5 strains 
of cluster 29 had the embB Met306Ile mutation, but 
1 of them also had the mutation embB Gly406Asp. 
Within cluster 4, two strains acquired the mutation 
embB Met306Ile independently, and 1 acquired embB 
Met306Val, as judged by the tree topology (Appen-
dix 1 Figure 4, panel B). Moreover, among all drug-
resistant strains, only 1 strain was identified with re-
sistance to pyrazinamide mediated by the mutation 
pncA Gln10Arg.
Discussion
By using conventional diagnostics and WGS, we 
showed that pulmonary TB in eastern Sudan is caused 
predominantly by L3 strains (Delhi/CAS). Drug re-
sistance and recent transmission were associated with 
L3 strains, accentuating the key role of L3 strains in 
TB epidemiology in eastern Sudan. In addition, most 
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Table 1. Demographic characteristics of tuberculosis patients 
investigated in eastern Sudan 
Characteristic 
No. recruited 
patients 
% Recruited 
patients 
Origin 
 Kassala 133 34.7 
 El-Gadarif 161 42.0 
 Port Sudan 89 23.3 
Sex 
 M 245 64.0 
 F 123 32.1 
 Not available 15 3.9 
Age, y 
 <25 76 19.8 
 25–40 170 44.4 
 >40 108 28.2 
 Not available 29 7.6 
Treatment history 
 Retreatment 21 5.5 
 New 312 81.5 
 Not available 50 13.0 
All patients 383 100 
 
 
Table 2. Comparison of Mycobacterium tuberculosis complex isolates sampled in eastern Sudan, 2014 and 2016* 
Variable 
Year of sample collection, no. (%) isolates 
Total no. p value 2014 2016 
Lineage    0.068 
 L3 51 (82.3) 71 (68.3) 122  
 Non-L3 11 (17.7) 33 (31.7) 44  
DST    0.019 
 Any drug resistance 20 (32.3) 16 (15.4) 36  
 No drug resistance 42 (67.7) 88 (84.6) 120  
<12 SNP cluster    0.016 
 Clustered 36 (58.1) 40 (38.5) 76  
 Not clustered 26 (41.9) 64 (61.5) 90  
All patients 62 (100) 104 (100) 166  
*DST, drug susceptibility testing; L, lineage; SNP, single-nucleotide polymorphism. 
 
SYNOPSIS
MDR TB cases were connected in 2 closely related mo-
lecular clusters (denoting recent transmission of MDR 
strains). This finding suggests that more focused 
infection control measures and contact tracing of 
patients with MDR TB need to be introduced to break 
the transmission chains at an early stage.
In this study, we found that a high proportion 
of culture-positive pulmonary TB cases (73.4%) were 
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Figure 2. MTBC population structure in eastern Sudan. Maximum-likelihood tree based on 11,932 concatenated single-nucleotide 
polymorphisms (SNPs) using a general time-reversible substitution model. Colored bars code for (inner to outer ring) MTBC lineages 
(L1–4); genotypic DST results stratified to MDR, non-MDR, and pansusceptible; sampling location; and clustered and nonclustered 
strains (SNP distance ≤12). MDR, multidrug resistant; MTBC, Mycobacterium tuberculosis complex.
M. tuberculosis Lineage 3, Eastern Sudan
caused by L3 strains. This finding is in line with 
previous studies that have been based on classical 
genotyping methods and reported rates of 40% or 
higher of the so-called Central Asia spoligotype fam-
ily in central and eastern Sudan (5,15,35). Moreover, 
Couvin et al. (36) identified Sudan as an L3 hotspot 
in Africa. In this regard, it is intriguing to speculate 
whether L3 strains in general or certain subgroups 
have developed particular pathobiologic properties 
rendering them more virulent in East Africa host 
populations. Recently, Stucki et al. (37) hypothesized 
a concept of generalists and specialist among L4 
strains based on the width of their geographic dis-
tribution. For L3 strains, larger studies are needed to 
reveal their global genetic diversity and geographic 
prevalence, which might inform about particular 
successful L3 subgroups and related causative vari-
ants in their genomes.
In addition to the general dominance of L3 
strains in eastern Sudan, we found that all MDR TB 
cases were caused exclusively by L3 strains. Of ma-
jor concern is that 10 of 15 MDR strains were part of 
2 genetically related clusters isolated mainly from 
patients treated in 2014 in Kassala hospital. At first 
glance, this finding suggested nosocomial transmis-
sion. However, 2 strains of these clusters were iso-
lated in 2016, including a strain from a patient treated 
in El-Gadarif hospital who had also acquired resis-
tance to ethambutol and pyrazinamide. This patient 
was the first patient in our study cohort infected 
with a fully first-line drug-resistant strain, clearly 
emphasizing the importance of adopting focused TB 
control measures, including rapid detection and ef-
fective treatment of patients with MDR TB, to better 
contain transmission of MDR strains and prevent de-
velopment of further drug resistances in the region. 
However, these measures are far from reality because 
proper TB diagnostics are virtually absent in eastern 
Sudan; other impeding factors are social stigma, lack 
of motivation, and poor awareness of TB treatment, 
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Table 3. Mutations conferring drug resistance among Mycobacterium tuberculosis complex genotypes identified in eastern Sudan, 
2014 and 2016* 
Genotype 
No. (%)  
strains 
No. (%) strains with mutations for drug No. (%) 
mutations/genotype 
No. (%) strains/genotype 
SM INH RIF EMB PZA Non-MDR  MDR  
Delhi/CAS 122 (73.5) 28 (85.0) 17 (100) 17 (100) 12 (100) 1 (100) 75 (93.75) 16 (76.1) 15 (100) 
EAI 4 (2.4) 0  0  0  0  0  0  0  0  
LAM 5 (3.0) 0  0  0  0  0  0  0  0  
Uganda 4 (2.4) 1 (3.0) 0  0  0  0  1 (1.25) 1 (4.8) 0  
S-type 2 (1.2) 0  0  0  0  0  0  0  0  
Haarlem 5 (3.0) 0  0  0  0  0  0  0  0  
Sudan H37Rv-like 4 (2.4) 0  0  0  0  0  0  0  0  
X-type 2 (1.2) 1 (3.0) 0  0  0  0  1 (1.25) 1 (4.8) 0  
Cameroon 2 (1.2) 0  0  0  0  0  0  0  0  
Euro-American 15 (9.0) 2 (6.0) 0  0  0  0  2 (2.5) 2 (9.5) 0  
Beijing 1 (0.6) 1 (3.0) 0  0  0  0  1 (1.25) 1 (4.8) 0  
Total 166 (100) 33 (100) 17 (100) 17 (100) 12 (100) 1 (100) 80 (100) 21 (100) 15 (100) 
*CAS, Central Asian strain; EAI, East African Indian; EMB, ethambutol; INH, isoniazid; LAM, Latin American Mediterranean; MDR, multidrug-resistant; PZA, 
pyrazinamide; RIF, rifampin; SM, streptomycin. 
 
 
Table 4. Performance of genotypic drug resistance prediction to first-line tuberculosis drugs in Mycobacterium tuberculosis complex  
strains, eastern Sudan* 
Drug 
Resistant 
 
Susceptible 
Se, %† 
(95% CI) 
Sp, %‡ 
(95% CI) 
PPV, %§ 
(95% CI) 
NPV, %¶ 
(95% CI) 
Unknown 
mutations 
(%) 
gR 
(TP) 
gS 
(FN) 
gU 
(FN) 
gR 
(FP) 
gS 
(TN) 
gU 
(TN) 
SM 24 0  9  0 133 0 72.7  
(54.5–86.7) 
100  100  93.7  
(89.4–96.3) 
9/166 
(5.4) 
INH 17 0 0  0 149 0 100  100  100  100  0/166 
(0.0) 
RIF 17 0 0  0 149 0 100  100  100  100  0/166 
(0.0) 
EMB 1 0 0  10* 155 0 100  93.9  
(89.1–97.1) 
9.10  
(5.2–15.4) 
100  0/166 
(0.0) 
PZA 1 0 0  0 165 0 100  100  100  100  0/166 
(0.0) 
*See MICs in the Methods section. EMB, ethambutol; FN, false negative; FP, false positive; gR, genetically resistant; gS, genetically susceptible; 
gU, genetic resistance unknown; INH, isoniazid; NPV, negative predictive value; PPV, positive predictive value; PZA, pyrazinamide; RIF, rifampin; Se, 
sensitivity; Sp, specificity; SM, streptomycin; TN, true negative; TP, true positive.  
†Se = TP  TP + FN.  
‡Sp = TN  TN + FP. 
§PPV =  TP  (TP + FP). 
¶NPV =  TN  (TN + FN).  
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with default rates of 14%–57% (38, 39). This situation 
may even lead to a further aggravation of the drug 
resistance problem through selection of MDR clones 
with additional drug resistances in failing treatment 
regimens and further transmission of fully first-line 
resistant MDR strains (14,39). However, our WGS 
analysis revealed that MDR isolates did not exhibit 
mutations mediating resistances to second-line drugs 
(except for isoniazid/ETH cross resistance), leaving 
reasonable therapeutic options for patients in eastern 
Sudan with MDR TB.
Former studies in central and eastern Sudan re-
ported drug resistances in 39%–67% and MDR in 
6%–22% of the strains investigated (4–10). Those 
variations could possibly be attributed to dissimi-
larities in study design, sample size, and character-
istics of study populations. In former studies, 53–235 
samples from only new or new and retreatment TB 
cases with unknown HIV status or with a propor-
tion of HIV-positive cases were investigated (4–10). 
Additionally, variations could also be linked to the 
laboratory technique used for pDST; for example, 
discordant results have been noticed between the 
BACTEC MGIT 960 and the proportion methods for 
streptomycin and ethambutol (40). In Sudan, only 1 
study used the BACTEC MGIT 960; the remaining 
studies used the proportion method on Löwenstein–
Jensen slants (4–10).
Considering the lack of pDST and the techni-
cal challenges associated with its implementation in 
Sudan, introduction of rapid molecular diagnostics 
to find patients with MDR TB is crucial for timely 
detection, treatment, and control. Moreover, rapid 
diagnostics will ultimately strengthen the national 
TB control program in Sudan. In line with previous 
studies, our data demonstrate an excellent perfor-
mance of gDST for molecular resistance prediction 
(16,17,41). One example of the benefits of molecular 
assays is the correction of false ethambutol suscep-
tibility results based on pDST in strains that harbor 
high-confidence embB resistance (42). Previous stud-
ies already revealed a low performance of ethambu-
tol pDST, attributable mainly to the small difference 
between the wild-type and mutant MIC levels, lead-
ing to the effect that strains with canonical embB mu-
tations show ethambutol MICs around the defined 
breakpoint of 5.0 µg/mL, resulting in a low repro-
ducibility of phenotypic results (24,25,42). There-
fore, classical Sanger sequencing of the embB codons 
306, 354, and 406 was recently proposed to over-
rule phenotypic ethambutol susceptibility results 
in cases of presence of mutations in these codons 
(42). Furthermore, Cepheid GeneXpert and Hain 
MTBDRplus version 2.0 would have recognized all 
rifampin-resistant mediating mutations in our study 
setting and, therefore, offer a rapid solution for iden-
tification of patients with MDR/rifampin-resistant 
TB in eastern Sudan.
This multisite study was conducted in 3 public 
hospitals in eastern Sudan, comprising 10%–20% of 
the TB cases in the region during the study period; it 
thus represents a snapshot of the population diver-
sity and transmission dynamics of MTBC strains in 
eastern Sudan. An additional strength of this study 
is that cultures, DSTs, and WGS were done in a 
World Health Organization–certified NRC in a high- 
resource setting in Germany, enabling maximum res-
olution for characterization of MTBC strains.
This study had >2 limitations. First, the pro-
longed transit time of patient-derived samples from 
Sudan to the NRC in Germany affected the viability 
of the MTBC bacteria; therefore, no mycobacterial 
growth was detected for some samples. Furthermore, 
the unavailability of clinical data, such as HIV status 
and treatment outcomes, prohibited further linking of 
bacteriological results to these clinical data.
In conclusion, L3 strains play a pivotal role in 
the epidemiology and transmission of TB, particu-
larly MDR TB, in eastern Sudan. Transmission of 
MDR TB could possibly be an emerging concern for 
local TB departments and hospitals. Therefore, to 
contain MDR TB transmission, rapid molecular di-
agnostics, such as Cepheid GeneXpert or Hain MT-
BDRplus v2.0, are desirable in combination with fo-
cused tracing of contacts of patients with MDR TB. 
In addition, early onset of MDR TB therapy would 
be an ideal approach to reduce the number of sec-
ondary cases.
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